EMD 128130 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3
156レット症候群1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001593-10-IT
(EUCTR)
02/12/200403/01/2005A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Name: Sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: Sarizotan hydrochloride
MERCK S.P.A.NULLNot RecruitingFemale: yes
Male: yes
Phase 3United Kingdom;Italy
2EUCTR2004-001594-25-ES
(EUCTR)
24/11/200402/11/2004A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2 Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Name: Sarizotan
Product Code: EMD 128130
INN or Proposed INN: Sarizotan Hydrochloride
MERCK KGaANULLNot RecruitingFemale: yes
Male: yes
600Phase 3Finland;Spain;Austria
3NCT00009048
(ClinicalTrials.gov)
January 200123/1/2001EMD 128130 for the Treatment of Parkinson's DiseaseEffect of Serotoninergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: EMD 128130;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth30Phase 2United States

156. レット症候群


臨床試験数 : 44 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004448-20-GB
(EUCTR)
28/11/201623/09/2016Sarizotan: Treatment in patients with Rett Syndrome with Respiratory Symptoms.A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms Rett syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10039000;Term: Rett's disorder;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Newron Pharmaceuticals S.p.A.NULLNot RecruitingFemale: yes
Male: yes
129Phase 2United States;Australia;Italy;United Kingdom;India